Glaxosmithkline Pharmaceuticals shareholding pattern
GLAXO
2603.6
0.00 (0.00%)Last updated on 17 Feb, 2026 | 15:51 IST
BUYSELL
The current prices are delayed, login to your account for live prices
Login Summary
For Year 2025-26, Glaxosmithkline Pharmaceuticals reports the following shareholding: Total Promoters at 75%, Mutual Fund at 4.77%, Insurance at 2.65%, Foreign Institutional Investors at 4.63%, Domestic Institutional Investors at 0.29%, and Retail at 12.66%. This breakdown provides a quick snapshot of ownership distribution for Glaxosmithkline Pharmaceuticals in 2025-26.
Glaxosmithkline Pharmaceuticals FAQs
As of 02-2026, the promoter shareholding in Glaxosmithkline Pharmaceuticals stands at 75% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.
The FII and DII shareholding of Glaxosmithkline Pharmaceuticals is 4.63% and 0.29% respectively.
The retail shareholding of the Glaxosmithkline Pharmaceuticals is 12.66%.
Changes in shareholding patterns of Glaxosmithkline Pharmaceuticals can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.
Shareholding patterns of Glaxosmithkline Pharmaceuticals are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.
The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.
Glaxosmithkline Pharmaceuticals Associated Pages
- Glaxosmithkline Pharmaceuticals Share Price
- Glaxosmithkline Pharmaceuticals Share Price chart
- Glaxosmithkline Pharmaceuticals Fundamental Analysis
- Glaxosmithkline Pharmaceuticals Technical Analysis
- Glaxosmithkline Pharmaceuticals Peer Comparison
- Glaxosmithkline Pharmaceuticals Share Price History
- Glaxosmithkline Pharmaceuticals Dividend
- Glaxosmithkline Pharmaceuticals Board of Directors